Alfa-Pharm Competitors and Similar CompaniesClear all

Alfa-Pharm's competitors and similar companies include Sientra, Paragon 28, Medela Italia and Guanhao Biotech.

	Alfa-Pharm Alfa-Pharm is a company that engages in the import, wholesaling, and retailing of medicines.	Sientra Sientra is a company that develops and sells medical aesthetics products.	Paragon 28 Paragon 28 is a medical device company focused on the foot and ankle orthopedic technologies.	Medela Italia Medela Italia is a company that supplies and distributes medical devices.	Guanhao Biotech Guanhao Biotech (冠昊生物科技股份有限公司) is a company that researches, develops, produces, and sells regeneration medical materials and implanted devices.
Founding Date	Founding Date 1996	Founding Date 2003	Founding Date 2010	Founding Date 1961	Founding Date N/A
Type	Type Private	Type Public	Type Public	Type Private	Type Public
Tags	Tags Healthcare distribution medical devices	Tags Healthcare distribution medical devices	Tags Healthcare medical devices medtech surgical solutions	Tags Healthcare distribution medical devices	Tags Healthcare distribution medical devices
Locations	Locations Yerevan, AM HQ	Locations Irvine, US HQ	Locations Englewood, US HQ Dublin, IE Ada, US	Locations Bargellino, IT HQ	Locations Guangzhou, CN HQ Beijing, CN Guangzhou, CN
Employees	Employees 1254% increase	Employees 3045% decrease	Employees 57424% increase	Employees 1,309	Employees 535
Valuation ($)	Valuation ($) N/A	Valuation ($) 2.1 m	Valuation ($) 433.6 m	Valuation ($) N/A	Valuation ($) 497.9 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $90.5m (FY, 2022)	Revenue (est.) $256.2m (FY, 2024)	Revenue (est.) N/A	Revenue (est.) ¥384.4m (FY, 2023)
Cost of goods	Cost of goods N/A	Cost of goods $49m (FY, 2022)	Cost of goods $64.7m (FY, 2024)	Cost of goods N/A	Cost of goods ¥84.4m (FY, 2023)
Gross profit	Gross profit N/A	Gross profit $41.6m (FY, 2022)	Gross profit $191.5m (FY, 2024)	Gross profit N/A	Gross profit ¥315.4m (FY, 2023)
Net income	Net income N/A	Net income ($73.3m) (FY, 2022)	Net income ($54.6m) (FY, 2024)	Net income N/A	Net income ¥21.1m (FY, 2023)